* Immunocore Holdings PLC IMCR.OQ IMCR.O is expected
to show a
rise in quarterly revenue when it reports results on August
10.
* The Abingdon Oxfordshire-based company is expected to
report a
180.8% increase in revenue to £15.901 million from £5.66 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Immunocore Holdings
PLC
is for a loss of 67 pence per share. For the same quarter last
year, the company reported a loss of 74 pence per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Immunocore
Holdings PLC is $56, above its last closing price of $54.40.
* Previous quarterly performance (using preferred earnings
measure
in pounds).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.82 -0.84 -0.37 Beat 56.2
Dec. 31 2022 -0.80 -0.82 -0.91 Missed -10.9
Sep. 30 2021 -0.75 -0.63 -0.68 Missed -8.1
Jun. 30 2021 -0.69 -0.68 -0.74 Missed -7.8
Mar. -0.59 -0.59 -0.66 Missed -12.5
31 2021
Dec. 31 2020 -0.76 -0.76 -0.62 Beat 22.4
This summary was machine generated August 8 at 07:32 GMT. All
figures in pounds unless otherwise stated